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Abstract
The role and regulation of the pleiotropic cytokine erythropoietin (EPO) in
skeletal muscle are controversial. EPO exerts its effects by binding its specific
receptor (EPO-R), which activates intracellular signaling and gene transcrip-
tion in response to internal and external stress signals. EPO is suggested to
play a direct role in myogenesis via the EPO-R, but several studies have ques-
tioned the effect of EPO treatment in muscle in vitro and in vivo. The lack of
certainty surrounding the use of nonspecific EPO-R antibodies contributes to
the ambiguity of the field. Our study demonstrates that the EPO-R gene and
protein are expressed at each stage of mouse C2C12 and human skeletal mus-
cle cell proliferation and differentiation and validates a specific antibody for
the detection of the EPO-R protein. However, in our experimental conditions,
EPO treatment had no effect on mouse C2C12 and human muscle cell prolif-
eration, differentiation, protein synthesis or EPO-R expression. While an
increase in Akt and MAPK phosphorylation was observed, we demonstrate
that this effect resulted from the stress caused by changing medium and not
from EPO treatment. We therefore suggest that skeletal muscle EPO-R might
be present in a nonfunctional form, or too lowly expressed to play a role in
muscle cell function.
Introduction
Erythropoietin (EPO) is a cytokine hormone primarily
dedicated to erythroid progenitor cell proliferation and
development. EPO exerts its effect by binding its specific
trans-membrane receptor, the EPO-receptor (EPO-R;
D’Andrea and Zon 1990; Youssoufian et al. 1993). In
erythroid progenitor cells, EPO-receptor binding leads to
the phosphorylation of cytoplasmic domain-associated
JAK2 proteins (Constantinescu et al. 1999; Remy et al.
1999), which in turn provokes STAT5 phosphorylation
and translocation to the nucleus where it activates gene
transcription (Damen et al. 1993; Pallard et al. 1995;
Penta and Sawyer 1995; Klingmuller et al. 1996; Quelle
et al. 1996). In addition, EPO activation of JAK2 activates
signaling cascades, such as the Ras/mitogen-activated
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kinase (MAPK) pathway and the phosphatidylinositol
3-kinase (PI3)/Akt pathway (Damen et al. 1993; Miura
et al. 1994; Constantinescu et al. 1999; Fisher 2003). Sev-
eral nonhematopoietic functions have been proposed for
EPO, including protection against oxidative stress in neu-
ronal cells (Zaman et al. 1999), neovascularisation in
uterine angiogenesis (Yasuda et al. 1998) and myocar-
dium maintenance and repair (Tada et al. 2006). Nonhe-
matopoietic EPO functions are also mediated by the
EPO-R, which is consequently expressed in numerous
nonhematopoietic tissues, including endothelial, neural,
muscle, cardiovascular and renal tissues, and is activated
in response to physical or metabolic stress (previously
reviewed in Noguchi et al. [2008]).
The pleiotropic roles of EPO have led to studies
investigating its potential role in controlling skeletal
muscle development and function. Ogilvie et al. (2000)
first reported the presence of the EPO-R mRNA and
protein in proliferating mouse C2C12 myoblasts and
primary satellite cells. More recently, several groups
provided evidence of EPO-R gene and/or protein
expression in human primary myoblasts and satellite
cells (Rundqvist et al. 2009; Launay et al. 2010) as well
as in human muscle tissue (Lundby et al. 2008;
Rundqvist et al. 2009; Christensen et al. 2012). However,
it is unknown if the EPO-R activates the same signaling
cascades in skeletal muscle as in hematopoietic cells.
While mouse C2C12 myoblasts treated with EPO dis-
played increases in JAK2, STAT5 (Ogilvie et al. 2000)
and Akt phosphorylation (Jia et al. 2012), such effects
could not be confirmed in rodent or human skeletal
muscle in vivo (LeBaron et al. 2007; Christensen et al.
2012). In line with its role in erythroid progenitor cells,
EPO promotes proliferation and survival and reduces
differentiation in mouse myoblasts (Ogilvie et al. 2000;
Jia et al. 2009). However, these effects could not be
repeated in human or rat myoblasts (Rotter et al. 2008;
Launay et al. 2010).
This lack of consistency across tissues and species
highlights the need for further systematic investigations.
Therefore, the aims of this study were to: first, thoroughly
examine the expression levels of the EPO-R gene and pro-
tein in mouse C2C12 and in human primary muscle cells
during muscle cell proliferation and differentiation. Sec-
ond, establish the effect of EPO treatment on human pri-
mary muscle cell proliferation, differentiation, as well as
the ability of EPO to induce EPO-R expression and to
activate the JAK2/STAT5, the Akt and the MAPK signal-
ing pathways in differentiated myotubes. Finally, as EPO
may activate Akt signaling, a key pathway involved in
muscle cell growth (Rommel et al. 2001), we investigated
for the first time the effect of EPO treatment on protein
synthesis in mouse C2C12 myotubes.
Materials and Methods
Cell culture and EPO treatment
Mouse C2C12 myoblasts (ATCC, Manassas, VA) were
plated in six-well tissue culture plates in complete Dul-
becco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (Life Technologies,
Mulgrave, Australia) and maintained in humidified air at
37°C and 5% CO2. As the cultures approached conflu-
ence, medium was changed to DMEM supplemented with
2% horse serum (HS) (Life Technologies). Differentiation
medium was replaced every 48 h.
Human primary myoblasts were plated in six-well tis-
sue culture plates previously coated with an extracellular
matrix (ECM) (Sigma, Castle Hill, Australia) in Hams F-
10 medium (Life Technologies) containing 20% FBS,
25 ng/mL fibroblast growth factor (bFGF) (Promega,
Madison, WI), 0.05% penicillin/streptomycin (Life
Technologies) and 0.05% amphoteromycin (Life Techno-
logies). Cells were maintained in humidified air at 37°C
and 5% CO2. At about 70% confluence, differentiation
was induced by replacing the medium by DMEM
supplemented with 2% HS. Differentiation medium was
replaced every 48 h.
All cell culture experiments were performed at least in
duplicate, using epoetin-a (EPO Recombinant Human
Protein, Life Technologies) and epoetin-b molecules
(NeoRecormon, Roche Australia, Dee Why, Australia)
at a concentration of 5 IU/mL, unless specified differ-
ently. Both epoetin-a and -b have been previously used
for in vitro EPO treatment at similar concentrations
(Ogilvie et al. 2000; Rotter et al. 2008; Launay et al.
2010; Jia et al. 2012). For cell culture experiments,
sample size was n = 3 unless specified differently. An
effect of medium change on increasing the phosphoryla-
tion of selected proteins was investigated by replacing
the differentiation medium with fresh medium
containing a vehicle control. To avoid acute stress effects
of medium replenishment, cells were serum starved for
12 h prior to EPO treatment with EPO then directly
spiked into the medium. Acute EPO treatment experi-
ments were paralleled by a negative control experiment
where a vehicle control was spiked into the medium.
Both EPO and vehicle control-treated cells were har-
vested at the same time points.
DNA sequencing
DNA sequencing was performed using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Life Technolgies, Mulgrave, Australia) accord-
ing to the manufacturer’s instructions. DNA sequencing
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products were then separated using capillary electrophore-
sis (ABI 3130xl Genetic Analyser, Applied Biosystems, Life
Technolgies).
Agarose gel electrophoresis
Agarose gels containing 0.1 lL/mL of SYBR Safe DNA
Gel Stain (Life Technologies) were prepared by using
10 mg/mL DNA Grade Agarose (Life Technologies) in
Tris-acetate-EDTA (TAE) buffer. DNA samples were
mixed with the Gel Loading Dye Orange (New England
Biolabs, Ipswich, MA) and loaded into the wells alongside
a 1 kb Plus DNA Ladder (Life Technolgies). Electropho-
resis was performed at 100 V and bands were visualized
using a UV transilluminator (Vilber Lourmat, Marne la
Vallee, France).
RNA extraction and real-time PCR
RNA was extracted using the Tri-Reagent Solution
(Ambion Inc., Austin, TX) according to the manufacturer’s
protocol. RNA concentration was assessed using the Nano-
drop 1000 Spectrophotometer (Thermo Fisher Scientific,
Waltham, MA). First-strand cDNA was generated from
1 lg RNA in 20 lL reaction buffer using the High Capacity
RT-kit (Life Technolgies); 19 RT buffer and random prim-
ers, 8 mmol/L dNTP and 2.5 U/lL MultiScribeTM RT
enzyme. The RT protocol consisted of 10 min at 25°C,
120 min at 37°C, 5 min at 85°C then cooled to 4°C.
Real-time PCR was carried out using a Stratagene
MX3000 thermal cycler (Agilent Technologies, Santa
Clara, CA). mRNA levels were measured using 19 SYBR
Green PCR Master Mix (Agilent Technologies) and 5 ng
of cDNA. All primers were used at a final concentration
of 300 nmol/L. Primer sequences are presented in
Table 1. The PCR condition conditions were 1 cycle of
10 min at 95°C; 40 cycles of 30 sec at 95°C, 60 sec at
60°C, 60 sec at 72°C; 1 cycle (melting curve) 60 sec at
90°C, 30 sec at 55°C, 30 sec at 95°C. To compensate for
variations in input RNA amounts and efficiency of the
reverse transcription, data were normalized to ribosomal
protein 36B4 (also known as RPLPO) mRNA levels.
Table 1. List of primers used for RT-PCR.
Gene (alias)
Human
GenBank accession number
Sequence 50–30
Mouse
GenBank accession number
Sequence 50–30
EPOR (EPO-R) NM_000121.3 NM_010149.3
Sense GAG CAT GCC CAG GAT ACC TA Sense CCC AAG TTT GAG AGC AAA GC
Anti CAT GGC CAC TAT GTC CAC AC Anti TGC AGG CTA CAT GAC TTT CG
CKTM2 NM_0010099735.1 NM_198415.2
Sense ACG CAC TGG CCG AAG CAT CC Sense ACG CAC TGG CCG AAG CAT CC
Anti GCC AGA TCG CCC TTC AGG CC Anti GCC AGA TCG CCC TTC AGG CC
MYH1 (MHC1) NM_000257.2 NM_080728.2
Sense ACC CTC AGG TGG CTC CGA GA Sense ACC CTC AGG TGG CTC CGA GA
Anti TGC AGC CCC AAA TGC AGC CA Anti TGC AGC CCC AAA TGC AGC CA
MYH2 (MHC2a) NM_001100112.1 NM_001039545.2
Sense GAT GGC ACA GAA GTT GCT GA Sense GAG CAA AGA TGC AGG GAA AG
Anti CTT CTC GTA GAC GGC TTT GG Anti TAA GGG TTG ACG GTG ACA CA
MYH4 (MHC2x) NM_005963.3 NM_030679.1
Sense AAG AGC AGG GAG GTT CAC AC Sense GGA CCC ACG GTC GAA GTT GCA
Anti TTA TCT CCA AAA GTC ATA AGT ACA Anti GGA ACT CAT GGC TGC GGG CT
VEGFA NM_001025366.2 NM_001025250.3
Sense GCG CAA GAA ATC CCG GTA TA Sense AAG CCA GCA CAT AGG AGA GAT GA
Anti GCT TTC TCC GCT CTG AGC AA Anti TCT TTC TTT GGT CTG CAT TCA CA
MYOD NM_002478.4 NM_010866.2
Sense CGT CGA GCA ATC CAA ACC A Sense CTG CTT CTT CAC GCC CAA A
Anti CTG CAG GCC CTC GAT ATA GC Anti CTG GAA GAA CGG CTT CGA AAG
MYC (c-MYC) NM_002467.4 NM_001177352.1
Sense TCG GGA AGT GGG AAA GCA Sense CCC AAA TCC TGT ACC TCG TC
Anti ATA GTT CCT GTT GGT GAA CCT AACG Anti GCG TAG TTG TGC TGG TGA GT
36B4 NM_001002.3 NM_007475.5
Sense TTG TGG GAG CAG ACA ATG TG Sense TTG TGG GAG CAG ACA ATG TG
Anti AGT CCT CCT TGG TGA ACA CG Anti AGT CCT CCT TGG TGA ACA CG
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
2014 | Vol. 2 | Iss. 3 | e00256
Page 3
S. Lamon et al. EPO-R and Skeletal Muscle
Protein extraction and western blot
Total protein was extracted using RIPA buffer (Millipore,
North Ryde, Australia) with 1 lL/mL protease inhibitor
cocktail (Sigma, Castle Hill, Australia) and 10 lL/mL
Halt Phosphatase Inhibitor Single-Use Cocktail (Thermo
Scientific, Rockford, IL). Total protein content was
determined using the BCA Protein Assay Kit (Pierce Bio-
technology, Rockford, IL) according to the manufac-
turer’s instructions.
Electrophoresis was performed using a 4–12% NuPAGE
Novex Bis-Tris Gel (Life Technolgies) in NuPAGE SDS
MOPS Running Buffer (Life Technolgies). Protein transfer
was performed in a Bjerrum buffer containing 50 mmol/L
Tris, 17 mmol/L glycine and 10% methanol using PVDF
membranes. The membranes were blocked with 5% BSA in
PBS, after which they were incubated at 4°C with the
following primary antibodies EPO-R (M-20, sc-697, Santa
Cruz Biotechnology, Santa Cruz, CA), phospho-Akt
(Ser473) (#9271, Cell Signalling Technology, Beverly, MA),
phospho-JAK2 (Tyr1007/Tyr1008) (sc-21870, Santa Cruz
Biotechnology, CA), phospho-STAT5 (pY694) (Life Tech-
nolgies), phospho-Erk1/2 (Thr202/Tyr204) (#4377, Cell
Signalling Technology). The primary antibodies were
diluted 1:1000 in PBS containing 5% BSA, except for phos-
pho-STAT5, which was diluted 1:500 in PBS containing 5%
skim milk. Following overnight incubation, the membranes
were washed and incubated for 1 h with an anti-rabbit IgG
antibody labeled with an infrared-fluorescent 800 nm dye
(Alexa Fluor 800, Life Technolgies) diluted 1:5000 in PBS
containing 50% Odyssey blocking buffer (LI-COR Bio-
sciences, Lincoln, NE) and 0.01% SDS. Membranes exposed
to the anti-phospho-JAK2 were incubated for 1 h with an
anti-goat IgG antibody labeled with an infrared-fluorescent
488 nm dye (Alexa Fluor 488, Life Technolgies) diluted
1:5000 in PBS containing 50% Odyssey blocking buffer
(LI-COR Biosciences) and 0.01% SDS. After washing, the
proteins were exposed on an Odyssey Infrared Imaging
System (LI-COR Biosciences) and individual protein band
optical densities were determined using the Odyssey Infra-
red Imaging System software. All blots were normalized
against the GAPDH protein (G8795, Sigma-Aldrich, Syd-
ney, Australia).
Protein sequencing
Isoelectric fractionation of human myotube
lysates
One milligram total protein from human myotube lysates
was precipitated in acetone as previously described
(Stephens et al. 2010) and resuspended in SB#2 buffer
(urea 7 mol/L, thiourea 2 mol/L, C7BzO 1% w/v). Intact
proteins were separated by isoelectric point using an Agi-
lent 3100 OFFGEL fractionator (Agilent Technologies)
according to the manufacturer’s instructions. Focusing
was carried out in 24 cm pH 3-10 ImmobilineTM DryStrip
(GE Healthcare, Uppsala, Sweden) at a constant 50 lA
for a total of 64,000 volt hours. On completion, proteins
from each fraction were collected and analyzed by western
blot for the presence of EPO-R. Fractions of interest were
concentrated using a 2D Cleanup kit (BioRad, Hercules,
CA) according to the manufacturer’s instructions and
resuspended in 80 lL of 29 Laemeli SDS-PAGE loading
buffer. Samples were snap-frozen and stored in 20 lL
aliquots at 80°C prior to analysis.
SDS-PAGE and western blot analysis
Offgel-concentrated fractions were separated by SDS-
PAGE using precast CriterionTM TGX Stain-freeTM 4–20%
polyacrylamide gels (BioRad). To determine the location
of bands reacting with EPO-R antibody, partial transfer
of proteins to low-fluorescence PVDF membrane (Milli-
pore, North Ryde, Australia) was undertaken for 90 sec at
a constant 2.5 A using a TransBlot TurboTM system (Bio-
Rad). This limited transfer time was empirically deter-
mined to transfer sufficient protein to the membrane for
western blotting, while leaving the remaining protein in
the SDS-PAGE gel for subsequent analysis by mass
spectrometry. Blocking primary and secondary antibody
conditions were the same as described above. Proteins
remaining in the SDS-PAGE gel were Coomassie-stained
overnight. To facilitate matching between images, a
minimum of three separate lanes in each gel contained
colorimetric protein standards (Precision Plus molecular
weight markers; BioRad), which were easily detected in
both gels and western blots following partial transfer.
Coomassie-stained gels were scanned using a ProPicII
robotic spotting platform (Genomic Solutions, Ann
Arbor, MI), and both the gel and western blot images
imported into Progenesis PG240 SameSpots software
(Non Linear Dynamics, Newcastle, UK). Triangulation
was performed using the molecular weight markers to
accurately align both images. The location of bands
detected by western blot was translated to the gel and
exported directly to the ProPic II robot as a series of x-y
coordinates. Bands containing the proteins of interest
were subsequently excised and deposited into microplates
for digestion and mass spectrometric analysis.
LC-MS/MS analysis of EPO-R bands excised from
SDS-PAGE gels
All proteins underwent tryptic digestion overnight using
standard procedures and MS/MS analysis and database
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searching were as previously described (Rainczuk et al.
2014). Spectra were subsequently interrogated for the
presence of peptides corresponding to the full-length or
soluble forms of EPO-R (UniPROT acc. P19235), using
BioTools 3.2SR3 software (version 3.2 build 5.65; Bruker
Daltonics, Bremen, Germany). The following search
parameters were allowed; enzyme trypsin, maximum two
missed cleavages; fixed modifications carbamidomethyla-
tion (C), variable modifications oxidation (M); 0.1 Da
MS tolerance; 0.8 Da MS/MS tolerance.
Protein synthesis assay
Protein synthesis was determined by measuring the
incorporation of radio-labeled [3H]-tyrosine (GE Health-
care, Sydney, Australia) into EPO-treated or control
mouse C2C12 myotubes (modified from Plaisance et al.
[2008]). Mouse C2C12 myotubes were also treated with
10 lmol/L dexamethasone (DEX) (Sigma-Aldrich, St.
Louis, MO) to induce catabolic stress or 100 nmol/L
insulin (INS) to induce anabolic stress. One lCi/mL of
radio-labeled [3H]-tyrosine and 2 mmol/L L-tyrosine
(Sigma-Aldrich) were added to the myotubes. The use of
excess nonradioactive tyrosine in the medium gives an
accurate indication of protein synthesis without altera-
tions in the free intracellular tyrosine pool (Vanden-
burgh et al. 1989). Following this, myotubes were
washed twice with cold phosphate-buffered saline (PBS)
and 1 mL of cold 10% trichloroacetic acid (TCA)
(Sigma-Aldrich) was added to each well. After scraping,
myotubes sat on ice for 1 h to precipitate the proteins,
followed by centrifugation at 20,000g for 10 min. The
supernatant was removed and the precipitates were dis-
solved in 0.1 mol/L NaOH containing 1% Triton X-100
(TX-100) (Sigma-Aldrich) overnight at room tempera-
ture. Following this, 400 lL of the sample was mixed
with 4 mL of Ultima Gold scintillation liquid (Perkin
Elmer, Boston, MA) and TCA soluble radioactivity was
measured using a Wallac1409 DSA liquid scintillation
counter (Perkin Elmer), as previously described by our
group (Foletta et al. 2013).
Proliferation assay
The rate of mouse C2C12 myoblast proliferation with
and without EPO treatment was assessed using the colori-
metric 5-bromo-20-deoxy-uridine (BrdU) Labeling and
Detection Kit III assay (Roche Applied Science, Indianap-
olis, IN) according to the manufacturer’s protocol.
Briefly, cells were plated at a concentration of 104 cells/
mL in a 96-well tissue culture plate. The BrdU label
reagent was added to the medium for 24 h prior to each
time point analysis. Nucleases were then used to fragment
DNA and BrdU incorporation into the DNA was detected
using a horseradish peroxidase conjugated anti-BrdU
antibody. Following the addition of the peroxidase sub-
strate ABTS (2,20-azino-bis, 3-ethylbenzthiazoline-6-sul-
fonic acid), fluorescence was detected at 405 nm.
Statistical analysis
All data are reported as mean  SEM. Gene and protein
expression during differentiation, myoblast proliferation
and protein synthesis were analyzed using a one-way
analysis of variance (ANOVA) or a two-way ANOVA.
Significant pairwise differences were detected using the
Student–Newman–Keul’s post hoc test. All other data
were analyzed using a two-tailed unpaired t-test. The level
of significance was set at P < 0.05.
Results
EPO-R gene expression in muscle cells
DNA sequencing returned sequences corresponding to the
mouse and human EPO-R transcripts, respectively (data
not shown). The EPO-R transcript was detected at each
stage of proliferation and differentiation in both mouse
C2C12 and human primary muscle cells. A transcript of
the same size was also detected in lysates from human
skeletal muscle tissue (Fig. 1A). EPO-R mRNA levels were
increased by approximately fivefold in confluent mouse
C2C12 myoblasts when compared to subconfluent myo-
blasts. This level of expression was then sustained during
myoblast to myotube differentiation (Fig. 1B). Inversely,
EPO-R mRNA levels decreased by about twofold as
human primary myoblasts terminally differentiated into
myotubes (Fig. 1C).
Identification and expression of the EPO-R
protein in muscle cells
Following western blotting using the EPO-R antibody
(M-20, sc-697, Santa Cruz Biotechnology), a single band
located slightly above 50 kDa corresponding to the full-
length EPO-R protein was detected at each stage of
mouse C2C12 and human primary muscle cell develop-
ment. The level of expression of the EPO-R protein
increased during differentiation in both types of cells,
although this increase was more dramatic in human pri-
mary muscle cells than in mouse C2C12 muscle cells. The
amount of EPO-R protein in fully differentiated human
myotubes was about 30-fold greater than in myoblasts,
whereas this increase was about threefold in mouse
C2C12 myotubes (Fig. 2A and B). Additionally, the anti-
body also detected a 50 kDa band in K-562 cells extracts,
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Jurkat cell lysates and in red blood cell extracts, which are
all commonly used as positive controls for EPO-R expres-
sion (Fig. 2C). To establish the specificity of the antibody
to detect the EPO-R protein, fractionation of myotube
lysates by isoelectric point and concentration of the
relevant fractions revealed three distinct bands (~55, 26,
A
B C
Figure 1. EPO-R gene expression during differentiation of mouse C2C12 cells or human primary muscle cells measured by (A) agarose gel
electrophoresis and (B, C) RT-PCR. (A) Agarose gel representing human EPO-R transcript expression in primary human skeletal muscle cells
during differentiation and in human muscle tissue extracts. Conf, confluent myoblasts; D1, day 1 after differentiation into myotubes; hM,
human muscle tissue extract; Neg, no cDNA control. EPO-R gene expression during differentiation: (B) mouse C2C12 cells, (C) human primary
muscle cells. SC, subconfluent myoblasts; Conf, confluent myoblasts; D1, day 1 after differentiation into myotubes. Data are represented as
mean  SEM. Significantly different from SC, *P < 0.05, **P < 0.01, ***P < 0.001.
A
C
B
Figure 2. EPO-R protein expression during differentiation of mouse C2C12 cells or human primary muscle cells. (A) Mouse C2C12 cells and (B)
human primary muscle cells. SC, subconfluent myoblasts; Conf, confluent myoblasts; D1, day 1 after differentiation into myotubes. Data are
represented as mean  SEM. *Significantly different from SC, P < 0.05. (C) EPO-R protein detection by western blotting using the M-20
antibody (sc-697, Santa Cruz Biotechnology).
2014 | Vol. 2 | Iss. 3 | e00256
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and 12 kDa) that reacted with the EPO-R antibody
(Fig. 3A). Each of these bands was excised from gels and
analyzed by LC-MS/MS for the presence of peptides cor-
responding to the EPO-R. In each case, multiple tryptic
peptides matching the EPO-R were observed (Fig. 3B and
Appendix 1). Moreover, further analysis revealed that in
the case of the 26 kDa reactive band, two of the identified
peptides corresponded to the C-terminal region (amino
acids 196–209) of the soluble form of the EPO-R (Fig. 3B
lower panel and Appendix 1). The data suggest that both
the membrane-bound and soluble forms of the EPO-R
are present in human myotube lysates.
A
B
Figure 3. Analysis of bands detected by the M-20 EPO-R antibody (sc-697, Santa Cruz Biotechnology). (A) Protein bands from human myotube
lysates that reacted with the anti-EPO-R antibody were identified by western blotting. Three consistently observed bands at ~55, ~26 and
~12 kDa were analyzed by mass spectrometry. Multiple lanes of standards were used for image triangulation during spot cutting. (B) Example
MS/MS spectra for peptides identified from the ~55 kDa full-length EPO-R (upper panel) or the ~26 kDa soluble EPO-R (lower panel, unique to
the soluble form). Additional peptides are listed in Appendix 1.
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The effect of EPO treatment on EPO-R gene
expression in muscle cells
Five IU/mL EPO treatment had no effect on the EPO-R
gene expression during mouse C2C12 or human primary
muscle cell proliferation or differentiation (Fig. 4). The
same result was observed for EPO-R protein expression
(data not shown).
The effect of EPO treatment on mouse
C2C12 myoblast proliferation
Treatment with EPO for 24, 48 and 72 h at 0.1 and 1 IU/
mL had no effect on mouse C2C12 myoblast proliferation
when compared to untreated cells. However, 5 IU/mL sig-
nificantly attenuated myoblast proliferation after 72 h of
treatment when compared to control cells (P < 0.01;
Fig. 5).
The effect of EPO treatment on muscle cell
differentiation
Five IU/mL EPO treatment had no effect on the mRNA
levels of the muscle differentiation markers CKMT2,
MHCI, MHCIIa, and MHCIIx, the angiogenic factor mar-
ker VEGFA, the myogenic factor MYOD and the cell cycle
regulator c-MYC at any stage of mouse C2C12 or human
primary muscle cell proliferation and differentiation (data
not shown).
The effect of medium replenishment on
molecular signaling
Replenishment of fresh medium can introduce cell stress
that may activate growth regulating kinases. This stress
may be mechanical, from removing and replenishing the
medium, or nutrient, from the fresh medium containing
cytokines and growth factors. Following medium change
in mouse C2C12 myotubes, Akt, JAK2, STAT5 and
ERK1/2 displayed an increase in phosphorylation at 15
and 30 min and had returned back to basal levels after
60 min (Fig. 6A). This effect was also observed, albeit to
a smaller extent, in human primary myotubes (data not
shown).
The effect of EPO treatment on molecular
signaling
To avoid stress caused by changing media, cells were
serum starved for 12 h before spiking EPO or a vehicle
directly into the medium. Fifteen, 30, 60 and 120 min
of EPO spike-in treatment had no effect on Akt phos-
phorylation in mouse C2C12 myotubes when compared
to cells treated with a vehicle control. Five, 15, 30, 60
and 120 min of EPO spike-in treatment had no effect
on JAK2, STAT5 and ERK1/2 phosphorylation either
(Fig. 6B). Insulin treatment phosphorylates Akt and this
was used as a positive control to demonstrate that the
myotubes were responsive. A 3.5- to 6.3-fold increase
in Akt phosphorylation was observed between 15 and
120 min of insulin treatment in mouse C2C12 myotu-
bes.
A B
Figure 4. EPO-R expression measured by RT-PCR during differentiation of mouse C2C12 cells or human primary muscle cells treated with EPO.
EPO treatment does not influence EPO-R gene expression during muscle cell differentiation. (A) Mouse C2C12 cells and (B) human primary
muscle cells. Data are represented as mean  SEM. Statistical analysis revealed no differences between groups at any of the time points.
Figure 5. BrDU proliferation assay. On mouse C2C12 myoblast
proliferation, 24 h, 48 h and 72 h EPO treatment has no effect.
Sample size was n = 6 for each group. Experiment was performed
in duplicate. Data are represented as mean  SEM. #Significantly
different from 24 h, P < 0.001. **Significantly different from CTRL,
P < 0.01.
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Similarly, in human primary myotubes, 15, 30, 60 and
120 min of EPO spike-in treatment had no effect on Akt,
JAK2, or STAT5 phosphorylation when compared to cells
treated with a vehicle control (Fig. 6C). Human primary
myotubes were sensitive to insulin as indicated by an
increase in Akt phosphorylation.
The same phenomenon was observed in mouse C2C12
and in human primary myoblasts where EPO spike-in
A
B
C
Figure 6. Medium replenishment but not acute EPO treatment phosphorylates Akt, JAK2, STAT5 and pERK1/2 in muscle cells. Fold-change
refers to the AU values normalized against GAPDH. (A) Effect of medium replenishment in mouse C2C12 cells, (B) effect of acute EPO
treatment in mouse C2C12 cells, (C) effect of acute EPO treatment in human primary muscle cells.
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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treatment had no effect on Akt activation (data not
shown).
The effect of EPO treatment on protein
synthesis in mouse C2C12 myotubes
One, 4 and 24 h of treatment with 5 IU/mL EPO had no
effect on protein synthesis in mouse C2C12 myotubes
when compared to untreated cells (Fig. 7). Insulin (INS)
and dexamethasone (DEX) increase and decrease muscle
protein synthesis, respectively, and were used as controls
to demonstrate that the cells were responsive to anabolic
and catabolic stimuli. As expected, 24 h of insulin treat-
ment induced anabolic stress and significantly augmented
protein synthesis by 1.4-fold (P < 0.001), whereas 24 h of
treatment with the catabolic agent dexamethasone signifi-
cantly decreased protein synthesis by 1.25-fold (P < 0.05).
Discussion
Erythropoietin has been considered as positive regulator
of skeletal muscle myogenesis and repair (Noguchi et al.
2008), however, numerous conflicting observations exist
within the field. Contributing to inconsistencies between
studies have been the use of muscle cells from different
species, comparisons made between in vitro and in vivo
experimental models and the use of nonspecific antibod-
ies (see Lamon and Russell [2013]). This study aimed to
clarify some of these inconstancies and several new obser-
vations were made. First, EPO-R gene expression was
confirmed in both mouse C2C12 and human primary
skeletal muscle myoblasts and myotubes using real-time
PCR followed by DNA sequencing. Second, for the first
time, western blotting followed by the use of LC-MS/MS
identified that the M-20 clone EPO-R antibody (Santa
Cruz) recognizes the EPO-R in mouse C2C12 and human
myoblast and myotube extracts. Third, spike-in treatment
of mouse C2C12 and human primary muscle cells with
EPO did not regulate proliferation, differentiation or pro-
tein synthesis. Finally, we observed that Akt, JAK2, STAT5
and ERK1/2 phosphorylation is sensitive to the stress of
changing culture medium and not due to EPO treatment.
In mouse C2C12 cells, EPO-R mRNA levels were
upregulated during myoblast proliferation, a result in
accordance with those of Ogilvie et al. (2000). However,
in this study the upregulation of EPO-R mRNA levels was
maintained during myoblast differentiation, in contrast to
results previously reported by Jia et al. (2012). Interest-
ingly, we observed the opposite pattern in human pri-
mary skeletal muscle cells. Here EPO-R mRNA levels were
highly expressed during myoblast proliferation but gradu-
ally decreased during differentiation into mature myotu-
bes. This pattern of EPO-R mRNA regulation in human
primary skeletal muscle cells is analogous to that observed
during erythropoiesis, where the EPO-R is not expressed
in mature red blood cells (Krantz 1991).
Expression of the EPO-R protein in skeletal muscle is a
contentious topic, mainly due to a wide controversy sur-
rounding the nonspecificity of certain commercially avail-
able EPO-R antibodies (previously reviewed in Lamon
and Russell [2013]). A study comparing several commer-
cially available EPO-R antibodies suggested that the M-20
clone (sc-697, Santa Cruz Biotechnology) was the only
antibody suitable for detection of the EPO-R protein by
western blot known to date (Elliott et al. 2006), although
the same group recently reported that, in a breast tumor
cell line (MCF-7), the M-20 antibody also bound to a
nonspecific protein migrating at a similar molecular
weight as the EPO-R (Elliott et al. 2013). Accordingly, we
report that the M-20 clone recognizes a single band at the
predicted size of the EPO-R in human skeletal muscle
and mouse C2C12 cell extracts. In order to assess the
specificity of this band with the greatest possible certainty,
we performed mass spectrometry on those proteins react-
ing with the EPO-R antibody. LC-MS/MS analysis
revealed peptides corresponding to the sequences of both
the full-length and soluble forms of human EPO-R. Our
results confirm for the first time the presence of the EPO-
R protein at each stage of myogenesis in mouse C2C12
and human skeletal muscle cells. In both mouse and
human muscle cells, the protein detected by the M-20
antibody was upregulated during differentiation. While
this regulatory pattern was similar to EPO-R gene expres-
sion in mouse C2C12 cells during differentiation, the
opposite was observed in human primary skeletal muscle
cells. The discrepancies existing between gene and protein
expression in human primary skeletal muscle cells, and
Figure 7. Protein synthesis assay. EPO treatment has no effect on
protein synthesis in mouse C2C12 myotubes. Sample size was
n = 6 for each group. Experiment was performed in duplicate. Data
are represented as mean  SEM. #Significantly different from 1 h,
P < 0.001. ***Significantly different from CTRL, P < 0.001.
*Significantly different from CTRL, P < 0.05.
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also between mouse C2C12 and human muscle cells, may
reflect a different function of EPO and its receptor in the
two species. This is not without precedent in the litera-
ture. In vivo, high-EPO dose injections increased mouse
exercise performance independently of erythropoiesis but
via the presence of EPO in the brain (Schuler et al.
2012); a result in contrast with human data (Rasmussen
et al. 2010). Previous studies have shown that mouse
C2C12 and human primary muscle cells can respond dif-
ferently to external stimuli (Czifra et al. 2006; Dogra et al.
2006, 2007a,b; Owens et al. 2013; Sharma et al. 2013).
Alternatively, the stability of the mature receptor protein
may vary between mouse and human muscle cells. Finally,
it cannot be excluded that the band recognized by the
EPO-R antibody contains more than one protein, as pre-
viously suggested with MCF-7 cell lysates (Elliott et al.
2013), although the negative control used in this particu-
lar study has not been validated. However, in order to
verify this hypothesis, another validated, commercially
available EPO-R antibody is required for the immunopre-
cipitation of the proteins. In addition, the lack of an eas-
ily accessible, validated negative control for the EPO-R
suggests that the protein expression results measured via
western blot should be considered carefully, as a partial
nonspecificity of the band may potentially account for the
observed differences.
EPO-R gene and protein expression was not altered
by EPO stimulation at any stage of differentiation in
mouse C2C12 and human primary skeletal muscle cells.
This is in contrast to previous studies suggesting that
EPO treatment triggers the expression of the EPO-R
gene and protein in mouse C2C12 myoblasts (Ogilvie
et al. 2000; Jia et al. 2009), but supports observations
that EPO administration does not regulate EPO-R
mRNA levels in human skeletal muscle (Lundby et al.
2008). In line with its role in erythroid progenitor cells,
EPO is proposed to enhance proliferation and survival
as well as reduce differentiation and fusion in mouse
C2C12 cells (Ogilvie et al. 2000; Jia et al. 2009, 2012).
However, we failed to observe an increase in mouse
C2C12 myoblast proliferation following EPO treatment
in our experimental conditions. Likewise, EPO treat-
ment in mouse C2C12 or human primary skeletal mus-
cle cells did not alter the expression of genes associated
with skeletal muscle cell differentiation, including the
myogenic factor MyoD. These results support those of
Launay et al. (2010), who reported that EPO supple-
mentation did not promote proliferation or postpone
differentiation in rat or human myoblasts cultured in
either normoxic or hypoxic conditions.
An increase in Akt signaling has been observed in
cultured mouse C2C12 myoblasts following EPO treat-
ment (Jia et al. 2012). Additionally, supraphysiological
levels of circulating EPO activated Akt in mouse skeletal
muscle (Hojman et al. 2009). Whether this activation
was EPO-R-dependent has not been established. We
consequently hypothesized that EPO may activate Akt in
human skeletal muscle cells. Additionally, as Akt
increases skeletal muscle hypertrophy, we were also
interested to determine whether EPO can increase mus-
cle cell protein synthesis (Rommel et al. 2001). We first
observed that in mouse C2C12 and human myotubes,
Akt, JAK2, STAT5 and ERK1/2 phosphorylation
increased following medium refreshment; an increase
that was independent of the presence of EPO in the
medium. This effect of medium change on the phos-
phorylation of signaling molecules in muscle cells is not
without precedent (Sinclair et al. 2010) and caution
should therefore be taken when manipulating cell cul-
ture treatments, while methodology should be precisely
stated. To eliminate the stress-related increase in Akt,
JAK2, STAT5 and ERK1/2 phosphorylation due to med-
ium change, EPO or a vehicle control was spiked
directly into the medium. EPO treatment did not lead
to any change in Akt, JAK2 and STAT5 phosphoryla-
tion. EPO has the potential to trigger the MAPK path-
way in interleukin-3-dependent cell lines expressing high
levels of EPO-R (Miura et al. 1994). However, we
observed no alteration in ERK1/2 phosphorylation fol-
lowing EPO treatment in mouse C2C12 myotubes.
Overall, these in vitro results support those recently
reported showing that acute EPO administration did not
lead to any change in the phosphorylation levels of
members of the Akt and MAPK signaling pathways in
human skeletal muscle in vivo (Christensen et al. 2012).
EPO treatment did not lead to any change in protein
synthesis in mouse C2C12 myotubes, although these
cells responded to both anabolic (insulin) and catabolic
stimuli (dexamethasone), a logical result considering
there was no increase in Akt phosphorylation.
Conclusion
In conclusion, we demonstrate here that EPO-R mRNA
and protein is expressed in both mouse C2C12 and
human primary skeletal muscle myoblasts and myotubes.
Our observations that EPO treatment, via a spike into the
medium, failed to regulate muscle cell proliferation, dif-
ferentiation or protein synthesis and did not influence
EPO-R expression or the phosphorylation levels of Akt,
JAK2, STAT5 or ERK1/2 questions the direct role of EPO
in muscle function; a question that has been previously
raised by several research groups (Launay et al. 2010;
Christensen et al. 2012). The use of overexpression and
knockdown strategies targeting the EPO-R in muscle cells
or rodent models is therefore crucial to improve our
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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understanding of the potential role that EPO and EPO-R
may play in skeletal muscle health.
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Appendix
A. Peptides identified by LC-MS/MS
corresponding to EPOR
Peak lists generated following LC-MS were examined for
the presence of peptides with expected masses corre-
sponding to EPO-R. Search paramaters: charge +1, MS
tolerance 0.1 Da, MS/MS tolerance 0.8 Da, enzyme Tryp-
sin, global modifications carbamidomethyl (C), optional
modifications oxidation (M) (see methods section for a
detailed description). The sequence of each EPO-R iso-
form is provided, with the location of matched peptides
shown in red.
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Band 1: 26 kDa Soluble EPOR
Band 2: 55 kDa Full length EPOR
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Band 3: ~12 kDa EPOR fragment
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B. Annotated MS/MS spectra
Annotated MS/MS spectra corresponding to matched
peptide sequences are provided with b and y ion series
shown in red or blue, respectively.
Band 1: 26 kDa Soluble EPOR
M/z 1705.876
Sequence: LCRLHQAPTARGAVR  2: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200 1400
      0.0
      0.5
      1.0
Abs. Int. * 1000
b R L H Q A A R G A
y V A G R A T P A Q H L R
197.247
y 1
247.283
b 2
247.283
y 2
460.503
b 3
346.408
y 3
544.471
b 4
388.495
y 4
660.534
b 5
544.471
y 5
787.482
b 6
646.530
y 6 874.554b 7
733.600
y 7
834.601
y 8
1046.687
b 9
900.431
y 9
1133.755
b 10
1028.733
y 10
1303.547
b 11
1133.755
y 111360.787
b 12
1303.547
y 12
1459.889
b 13
M/z 1661.884
Sequence: WLPPPETPMTSHIR
m/z200 300 400 500 600 700 800 900
      0.0
      0.5
      1.0
Abs. Int. * 1000
b W L P P P E
y I H S
197.217
b 1
288.245
b 2
288.245
y 2
402.293
b 3
426.249
y 3
500.263
b 4
500.263
y 4
557.338
b 5
713.434
b 6
713.434
y 6
949.311
b 8
949.311
y 8
M/z 1608.789
Sequence: YEVDVSAGNGAGSVQR
m/z200 400 600 800 1000 1200 1400
     0
     2
     4
     6
Abs. Int. * 1000
b Y E V D V S A G N G
y R Q V S G A G N G A S
175.119
b 1
175.119
y 1
288.114
b 2
288.114
y 2
385.073
b 3
402.096
y 3
520.073
b 4
464.076
y 4
611.099
b 5
520.073
y 5
695.133
b 6
611.099
y 6
729.154
b 7
685.135
y 7
827.121
b 8
827.121
y 8
915.288
b 9
844.194
y 9
1014.341
b 10
915.288
y 10
1014.341
y 11
1233.360
b 13
1233.360
y 13
M/z 1565.74
Sequence: GTVFLSPDWLSSTR
m/z200 400 600 800 1000 1200 1400
      0.0
      0.5
      1.0
Abs. Int. * 1000
b V F L S P D W R
y R T S S L W D P
175.069
y 1
154.162
b 2
266.115
y 2
266.115
b 3
367.155
y 3
395.118
b 4
446.216
y 4
511.179
b 5
574.287
y 5
626.201
b 6
740.338
y 6
711.366
b 7
855.353
y 7
839.341
b 8
975.364
y 8
992.480
b 9
1365.981
b 13
1506.698
y 13
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Band 2: 55 kDa Full Length EPOR
M/z 1565.724
Sequence: GTVFLSPDWLSSTR
m/z200 400 600 800 1000 1200 1400
     0
   200
   400
Abs. Int. 
b F L S P D W
y S S L W D P
267.383
y 2
267.383
b 3
374.393
y 3
374.393
b 4
463.472
y 4
511.474
b 5
528.502
y 5
626.543
b 6
727.601
y 6
683.559
b 7
839.575
y 7
839.575
b 8
992.721
y 8
992.721
b 9
M/z 1350.621
Sequence: GPEELLCFTER  7: Carbamidomethyl (C)
m/z200 300 400 500 600 700 800 900 1000 1100 1200
     0
   100
   200
   300
   400
   500
Abs. Int. 
y E T F C* L P
333.242
y 2
402.144
y 3
402.144
b 4 592.224
y 4
716.316
y 5
809.555
y 6
809.555
b 7
1213.932
y 9
1213.932
b 10
1259.640
y 10
M/z 2272.102
Sequence: IWPGIPSPESEFEGLFTTHK 
m/z200 400 600 800 1000 1200 1400 1600 1800 2000
     0
     5
    10
    15
Abs. Int. * 1000
b P G I P S P E S E F E G L F T T
y H T T F L G E F E S E P S G P
299.456
b 2
287.367
y 2
396.641
b 3
387.602
y 3
445.731
b 4
495.786
y 4
574.843
b 5
623.889
y 5
681.875
b 6
732.844
y 6
760.932
b 7
803.897
y 7
823.972
b 8
916.908
y 8
969.036
b 9
1079.988
y 9
1079.988
b 10
1193.572
y 10
1193.572
b 11
1292.055
y 11
1310.112
b 12
1431.928
y 12
1454.136
b 13
1512.997
y 13
1512.997
b 14
1583.142
y 14
1649.998
b 15
1748.964
b 16
1827.791
y 16
1881.172
b 17
1876.906
y 17
M/z 2272.098
Sequence: IWPGIPSPESEFEGLFTTHK 
m/z200 400 600 800 1000 1200 1400 1600 1800 2000
     0
     2
     4
     6
Abs. Int. * 1000
b P G I P S P E S E F E G L F T
y H T T F L G E F E S E P S
297.457
b 2
297.457
y 2
396.686
b 3
387.622
y 3
456.719
b 4
495.824
y 4
574.895
b 5
623.912
y 5
681.926
b 6
732.890
y 6
760.985
b 7
803.925
y 7
824.024
b 8
916.924
y 8
969.105
b 9
1079.092
y 9
1076.993
b 10
1205.968
y 10
1181.207
b 11
1306.082
y 11
1310.183
b 12
1450.078
y 12
1454.249
b 13
1513.060
y 13
1513.060
b 14
1584.308
y 14
1650.086
b 15
1753.386
b 16
1881.436
b 17
1877.050
y 17
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
2014 | Vol. 2 | Iss. 3 | e00256
Page 17
S. Lamon et al. EPO-R and Skeletal Muscle
M/z 1959.951
Sequence: AALLAARGPEELLCFTER
m/z200 400 600 800 1000 1200 1400 1600
     0
     2
     4
     6
     8
Abs. Int. * 1000
b A L L A A R G P E E L L C F T E
y R E T F C L L E E P G R L
86.034
b 1
179.153
y 1
147.122
b 2
302.344
y 2
266.352
b 3
409.600
y 3
371.485
b 4
558.703
y 4
439.588
b 5 654.761
y 5
516.606
b 6 766.860y 6
668.747
b 7
880.648
y 7
710.873
b 8
1012.030
y 8
809.921
b 9
1139.320
y 9953.073
b 10
1218.413
y 10 1081.256
b 11
1287.813
y 11
1200.346
b 12 1438.830
y 12
1305.606
b 13
1410.812
b 14
1549.211
b 15
1695.623
y 15
1665.953
b 16
1830.617
y 16
M/z 1888.007
Sequence: VEILEGRTECVLSNLR  10: Carbamidomethyl (C)
m/z100 200 300 400 500 600 700 800 900 1000
     0
   100
   200
   300
   400
   500
Abs. Int. 
b V L E G E
y R L N S L V
175.150
y 1
322.444
y 2
338.530
b 3
409.598
y 3
472.670
b 4
489.658
y 4
593.802
b 5
604.780
y 5
607.869
b 6
708.833
y 6
922.015
b 8
1064.747
b 9
1081.839
y 9
M/z 1887.994
Sequence: VEILEGRTECVLSNLR  10: Carbamidomethyl (C)
m/z200 300 400 500 600 700 800 900 1000
     0
   100
   200
   300
   400
Abs. Int. 
b L E G R
y R S L V
169.068
y 1
374.570
b 3
409.639
y 3
489.656
b 4
489.656
y 4
586.682
b 5
603.726
y 5
607.785
b 6
708.791
y 6 789.840b 7
M/z 1887.991
Sequence: VEILEGRTECVLSNLR  10: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200 1400 1600
     0
    10
    20
    30
Abs. Int. * 1000
b V E I L E G R T E C* V L S R
y R L N S L V C* E T R G E L I E
101.147
b 1
175.342
y 1
230.507
b 2
286.618
y 2
338.756
b 3
403.852
y 3
454.872
b 4
489.934
y 4
586.981
b 5
604.996
y 5
647.152
b 6
706.665
y 6
792.632
b 7
897.082
y 7
897.082
b 8
995.082
y 8
1022.018
b 9
1082.104
y 9
1181.148
b 10
1265.173
y 10
1282.130
b 11
1282.130
y 11
1400.131
b 12
1400.131
y 12
1480.132
b 13
1551.173
y 13
1671.141
y 14
1713.954
b 15
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M/z 1887.989
Sequence: VEILEGRTECVLSNLR  10: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200 1400 1600
     0
     1
     2
     3
     4
     5
Abs. Int. * 1000
b E I L E G R T E C* V L S R
y R L N S L V C* R G I
109.972
b 1
175.245
y 1
209.339
b 2
286.464
y 2
338.614
b 3
409.709
y 3
455.665
b 4 489.759y 4
586.828
b 5
604.833
y 5
637.774
b 6
706.449
y 6
792.504
b 7
897.937
y 7
897.937
b 8
1039.877
b 9
1085.010
y 9
1180.961
b 10
1283.083
y 10
1283.083
b 11
1283.083
y 11
1381.182
b 12
1481.156
b 13
1551.180
y 13
1689.097
y 14
1731.819
b 15
1844.418
b 16
M/z 1887.989
Sequence: VEILEGRTECVLSNLR  10: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200 1400 1600
     0
     1
     2
     3
Abs. Int. * 1000
b E I L E G R T E C* V
y R L N S L V T R G
175.207
y 1
209.352
b 2
286.509
y 2
338.631
b 3
409.750
y 3
472.725
b 4
489.774
y 4
586.832
b 5
604.851
y 5
664.999
b 6
706.503
y 6
792.473
b 7
914.845
b 8
973.952
y 8
1039.848
b 9
1081.902
y 9
1181.064
b 10
1281.985
y 10
1281.985
b 11
1281.985
y 11
1514.985
b 13
1550.891
y 13
M/z 1887.982
Sequence: VEILEGRTECVLSNLR  10: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200 1400 1600
     0
     5
    10
    15
    20
    25
Abs. Int. * 1000
b V E I L E G R T E C* V L S R
y R L N S L V C* E T R G I E
110.034
b 1
175.257
y 1
239.407
b 2
286.530
y 2
338.622
b 3
401.648
y 3
454.748
b 4
489.787
y 4
586.828
b 5
604.843
y 5
625.096
b 6
706.526
y 6
792.472
b 7
897.880
y 7
897.880
b 8
985.930
y 8
1039.944
b 9
1084.301
y 9
1180.987
b 10
1282.019
y 10
1282.019
b 11
1282.019
y 11
1381.030
b 12
1480.100
b 13
1551.971
y 13
1687.967
y 14
1713.874
b 15
1789.901
y 15
M/z 1608.813
Sequence: YEVDVSAGNGAGSVQR 
m/z200 400 600 800 1000 1200 1400
      0.0
      0.2
      0.4
      0.6
      0.8
      1.0
Abs. Int. * 1000
b E V D V S A G N G A G S V
y Q V S G A G N G A S V D V
289.290
b 2
311.259
y 2
402.266
b 3
402.266
y 3
513.298
b 4
489.362
y 4
617.416
b 5
531.314
y 5
687.444
b 6
617.416
y 6
758.405
b 7
687.444
y 7
851.536
b 8
758.405
y 8
905.498
b 9
851.536
y 9
965.581
b 10
905.498
y 10
1078.690
b 11
965.581
y 11
1102.619
b 12
1102.619
y 12
1207.754
b 13
1207.754
y 13
1320.920
b 14
1320.920
y 14
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M/z 1561.757
Sequence: TECVLSNLRGRTR  3: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200
     0
   100
   200
   300
Abs. Int. 
b L S N
y T R G R L N
175.333
y 1
243.343
b 2
243.343
y 2
438.448
y 3
509.473
b 4
509.473
y 4
638.521
b 5
638.521
y 5
682.641
b 6
731.694
y 6
836.758
b 7
836.758
y 7
1397.118
b 12
M/z 1561.749
Sequence: TECVLSNLRGRTR  3: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200 1400
     0
     1
     2
     3
Abs. Int. * 1000
b T E C* V L S N L
y R T R G R L N S E
112.093
b 1
175.119
y 1
229.161
b 2
274.281
y 2
410.147
b 3
438.178
y 3
481.215
b 4
481.215
y 4
610.249
b 5
638.267
y 5
682.295
b 6
773.361
y 6
801.399
b 7
882.428
y 7
933.442
b 8
961.506
y 8
1302.855
b 11
1320.001
y 11
1464.249
y 12
M/z 1350.657
Sequence: GPEELLCFTER  7: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200
     0
   100
   200
   300
Abs. Int. 
b P E E L L R
y R E T F P
175.119
y 1
175.119
b 2
293.038
y 2
284.136
b 3
431.140
y 3
431.140
b 4
570.106
y 4
518.123
b 5
671.114
b 6
1197.855
y 9
1197.855
b 10
1306.642
y 10
M/z 1350.643
Sequence: GPEELLCFTER  7: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200
     0
   100
   200
   300
   400
   500
Abs. Int. 
b E E L L C* R
y R E T F C* L P
175.119
y 1
175.119
b 2
284.188
y 2
284.188
b 3
413.115
y 3
413.115
b 4
554.647
y 4
516.159
b 5
688.209
y 5
671.232
b 6
835.229
y 6
835.229
b 7
1168.713
y 9
1168.713
b 10
1305.609
y 10
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M/z 1265.649
Sequence: LCRLHQAPTAR 
m/z200 300 400 500 600 700 800 900 1000 1100
     0
    50
   100
   150
   200
Abs. Int. 
b R L H Q A P T
y R P A Q H L
197.295
b 2
338.327
b 3
338.327
y 3
460.359
b 4
460.359
y 4
607.428
b 5
532.401
y 5
738.635
b 6
607.428
y 6 826.810
b 7
778.514
y 7
905.536
b 8
905.536
y 8
1006.746
b 9 1229.026
b 11
1229.026
y 11
M/z 1226.672
Sequence: GRTRYTFAVR 
m/z100 200 300 400 500 600 700 800 900 1000 1100
      0.0
      0.2
      0.4
      0.6
      0.8
      1.0
Abs. Int. * 1000
b R T
y R V A
175.119
y 1
197.205
b 2
295.055
y 2
312.085
b 3
357.094
y 3
1164.763
y 9
M/z 829.537
Sequence: VTAASGAPR 
m/z100 200 300 400 500 600 700
     0
     2
     4
Abs. Int. * 1000
b V T A A S G A P R
y R P A G S A A
112.076
b 1
175.109
y 1
197.091
b 2
272.152
y 2
272.152
b 3
332.196
y 3
332.196
b 4
402.260
y 4
421.122
b 5
461.202
y 5
461.202
b 6
558.418
y 6
558.418
b 7
645.578
y 7
645.578
b 8
787.903
b 9
M/z 829.529
Sequence: VTAASGAPR 
m/z100 200 300 400 500 600 700
      0.0
      0.5
      1.0
      1.5
      2.0
Abs. Int. * 1000
b V T A A S
y R P A G
112.052
b 1
175.124
y 1
197.084
b 2
272.161
y 2
272.161
b 3
332.181
y 3
332.181
b 4
385.252
y 4
421.127
b 5
558.545
y 6
558.545
b 7
787.732
b 9
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Band 3: ~12 kDa EPOR fragment
M/z 815.518
Sequence: VEILEGR 
m/z200 300 400 500 600 700
     0
   100
   200
   300
   400
Abs. Int. 
b E I L R
y R G E L I
112.226
b 1
175.243
y 1
255.292
b 2
255.292
y 2
358.328
b 3
358.328
y 3
445.444
b 4
445.444
y 4
624.369
y 5
628.437
b 6
769.541
b 7
M/z 1608.813
Sequence: YEVDVSAGNGAGSVQR 
m/z200 400 600 800 1000 1200 1400
      0.00
      0.25
      0.50
      0.75
      1.00
Abs. Int. * 1000
b E V D V S A G N G A G S V
y Q V S G A G N G A S V D V
289.290
b 2
311.259
y 2 402.266
b 3
402.266
y 3
513.298
b 4
489.362
y 4
617.416
b 5
531.314
y 5
687.444
b 6
617.416
y 6
758.405
b 7
687.444
y 7
851.536
b 8
758.405
y 8
905.498
b 9
851.536
y 9
965.581
b 10
905.498
y 10
1078.690
b 11
1102.619
b 12
1207.754
b 13
M/z 1561.749
Sequence: TECVLSNLRGRTR  3: Carbamidomethyl (C)
m/z200 400 600 800 1000 1200 1400
     0
     1
     2
     3
Abs. Int. * 1000
b T E C* V L S N L
y R T R G R L N S E
112.093
b 1
175.119
y 1
229.161
b 2
274.281
y 2
410.147
b 3
438.178
y 3
481.215
b 4
481.215
y 4
610.249
b 5
638.267
y 5
682.295
b 6
773.361
y 6
801.399
b 7
882.428
y 7
933.442
b 8
961.506
y 8
1302.855
b 11
1320.001
y 11
1464.249
y 12
M/z 1226.672
Sequence: GRTRYTFAVR 
m/z100 200 300 400 500 600 700 800 900 1000 1100
      0.00
      0.25
      0.50
      0.75
      1.00
Abs. Int. * 1000
b R T
y R V A
175.119
y 1
197.205
b 2
295.055
y 2
312.085
b 3
357.094
y 3 1164.763
y 9
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